Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2019

Open Access 01-12-2019 | Care | Study protocol

Cost-effectiveness of a lifestyle intervention for people with a serious mental illness (SMILE): design of a pragmatic cluster-randomised controlled trial

Authors: Florine S. Walburg, Berno van Meijel, Maurits W. van Tulder, Marcel C. Adriaanse

Published in: BMC Psychiatry | Issue 1/2019

Login to get access

Abstract

Background

Cardiovascular disease is the leading cause of the estimated 11–25 years reduced life expectancy for persons with serious mental illness (SMI). This excess cardiovascular mortality is primarily attributable to obesity, diabetes, hypertension, and dyslipidaemia. Obesity is associated with a sedentary lifestyle, limited physical activity and an unhealthy diet. Lifestyle interventions for persons with SMI seem promising in reducing weight and cardiovascular risk. The aim of this study is to evaluate the effectiveness and cost-effectiveness of a lifestyle intervention among persons with SMI in an outpatient treatment setting.

Methods

The Serious Mental Illness Lifestyle Evaluation (SMILE) study is a cluster-randomized controlled trial including an economic evaluation in approximately 18 Flexible Assertive Community Treatment (FACT) teams in the Netherlands. The intervention aims at a healthy diet and increased physical activity. Randomisation takes place at the level of participating FACT-teams. We aim to include 260 outpatients with SMI and a body mass index of 27 or higher who will either receive the lifestyle intervention or usual care. The intervention will last 12 months and consists of weekly 2-h group meetings delivered over the first 6 months. The next 6 months will include monthly group meetings, supplemented with regular individual contacts. Primary outcome is weight loss. Secondary outcomes are metabolic parameters (waist circumference, lipids, blood pressure, glucose), quality of life and health related self-efficacy. Costs will be measured from a societal perspective and include costs of the lifestyle program, health care utilization, medication and lost productivity. Measurements will be performed at baseline and 3, 6 and 12 months.

Discussion

The SMILE intervention for persons with SMI will provide important information on the effectiveness, cost-effectiveness, feasibility and delivery of a group-based lifestyle intervention in a Dutch outpatient treatment setting.

Trial registration

Dutch Trial Registration NL6660, registration date: 16 November 2017.
Literature
1.
Laursen TM, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H, Gissler M, Nordentoft M. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013;8:e67133.CrossRefPubMedPubMedCentral
2.
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–31.CrossRefPubMed
3.
Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620–7.CrossRefPubMed
4.
HERT M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, MÖLLER HJ, Ndetei DM. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.CrossRef
5.
DEH M, Schreurs V, Vancampfort D, VANW R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.CrossRef
6.
Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–47.CrossRefPubMedPubMedCentral
7.
Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions. Frontiers in psychiatry. 2014;5:137.CrossRefPubMedPubMedCentral
8.
Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open. 2013;3:e002808.CrossRefPubMedPubMedCentral
9.
National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. NICE guidelines 2014. [CG178].
10.
van Meijel B: multidisciplinaire richtlijn Leefstijl bij patiënten met een ernstige psychische aandoening. Verpleegkundigen & Verzorgenden Nederland (V&VN) 2015, 2015.
11.
Speyer H, Christian Brix Nørgaard H, Birk M, Karlsen M, Storch Jakobsen A, Pedersen K, Hjorthøj C, Pisinger C, Gluud C, Mors O. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15:155–65.CrossRefPubMedPubMedCentral
12.
Naslund JA, Whiteman KL, McHugo GJ, Aschbrenner KA, Marsch LA, Bartels SJ. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2017;47:83–102.CrossRefPubMedPubMedCentral
13.
Osborn D, Burton A, Hunter R, Marston L, Atkins L, Barnes T, Blackburn R, Craig T, Gilbert H, Heinkel S, et al. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial. Lancet Psychiatry. 2018.
14.
Yarborough BJH, Leo MC, Stumbo S, Perrin NA, Green CA. STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications. BMC psychiatry. 2013;13:238.CrossRefPubMedPubMedCentral
15.
Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, Perrin NA, Nichols GA, Stevens VJ. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172:71–81.CrossRefPubMed
16.
Yarborough BJH, Leo MC, Yarborough MT, Stumbo S, Janoff SL, Perrin NA, Green CA. Improvement in body image, perceived health, and health-related self-efficacy among people with serious mental illness: the STRIDE study. Psychiatr Serv. 2015;67:296–301.CrossRefPubMedPubMedCentral
17.
18.
Nugter MA, Engelsbel F, Bahler M, Keet R, van Veldhuizen R. Outcomes of FLEXIBLE assertive community treatment (FACT) implementation: a prospective real life study. Community Ment Health J. 2016;52:898–907.CrossRefPubMed
19.
McGaghie WC, Watson DL, Tharp RG: Self-directed behavior: self-modification for personal adjustment. JSTOR; 1974.
20.
Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.CrossRefPubMed
21.
Burke BL, Arkowitz H, Dunn C. The efficacy of motivational interviewing and its adaptations: what we know so far. Motivational interviewing: Preparing people for change. 2002;2:217–50.
22.
Rollnick S, Mason P, Butler C: Health behavior change: a guide for practitioners. Elsevier Health Sciences; 1999.
23.
Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23:325–34.CrossRef
24.
Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.CrossRefPubMed
25.
Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert review of pharmacoeconomics & outcomes research. 2004;4:515–23.CrossRef
26.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral
27.
Versteegh M, M. Vermeulen K, M. A. A. Evers S, de Wit GA, Prenger R, Stolk EA: Dutch tariff for the five-level version of EQ-5D. Value Health 2016, 19:343–352.
28.
Rademakers J, Nijman J, van der Hoek L, Heijmans M, Rijken M. Measuring patient activation in the Netherlands: translation and validation of the American short form patient activation measure (PAM13). BMC Public Health. 2012;12(1).
29.
Buuren Sv G-OK. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2010:1–68.
30.
Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Naslund JA, Wolfe R, Xie H, McHugo GJ, Jimenez DE, Jue K, et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry. 2015;172:344–52.CrossRefPubMed
31.
Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV 3rd, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368:1594–602.CrossRefPubMedPubMedCentral
32.
Prochaska JO. Transtheoretical model of behavior change. In: Encyclopedia of behavioral medicine, vol. 2013: Springer. p. 1997–2000.
33.
Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55:305–12.PubMedPubMedCentral
34.
Rollnick S, Allison, J, Ballasiotes S, Barth T, Butler CC, Rose GS, Rosengren D. Variations on a theme: motivational interviewing and its adaptations. Motivational interviewing: preparing people for change. Guilford Press New York. 2002; 270–283.
35.
Brink L, Postma-Smeets A, Stafleu A, Wolvers D: Richtlijnen schijf van vijf. Voedingscentrum Nederland; 2016.
36.
Gezondheidsraad. Beweegrichtlijnen 2017. vol. 2017/08. Den Haag: Gezondheidsraad; 2017.
Metadata
Title
Cost-effectiveness of a lifestyle intervention for people with a serious mental illness (SMILE): design of a pragmatic cluster-randomised controlled trial
Authors
Florine S. Walburg
Berno van Meijel
Maurits W. van Tulder
Marcel C. Adriaanse
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Care
Published in
BMC Psychiatry / Issue 1/2019
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-019-2132-5

Other articles of this Issue 1/2019

BMC Psychiatry 1/2019 Go to the issue

Research article

STructured lifestyle education for people WIth SchizophrEnia (STEPWISE): mixed methods process evaluation of a group-based lifestyle education programme to support weight loss in people with schizophrenia

Research article

A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder

Research article

Prevalence and determinants of symptoms of antenatal common mental disorders among women who had recently experienced an earthquake: a systematic review

Research article

Efficacy and feasibility of a humor training for people suffering from depression, anxiety, and adjustment disorder: a randomized controlled trial

Research article

Prevalence of prolonged grief disorder in a sample of female refugees

Study protocol

Evaluation of a structured skills training group for adolescents with attention deficit/hyperactivity disorder (ADHD) – study protocol of a randomised controlled trial